Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Status: | Active, not recruiting |
---|---|
Conditions: | Skin Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/9/2019 |
Start Date: | August 8, 2008 |
A Phase III Randomized Trial of Chemotherapy With or Without Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
This randomized phase III trial studies chemotherapy to see how well it works with or without
bevacizumab in treating patients with head and neck squamous cell carcinoma that has come
back (recurrent) or that has spread to other parts of the body (metastatic). Drugs used in
chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may
interfere with the ability of tumor cells to grow and spread. Bevacizumab may also make tumor
cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking
blood flow to the tumor. It is not yet known whether combination chemotherapy is more
effective when given with or without bevacizumab in treating patients with head and neck
squamous cell carcinoma.
bevacizumab in treating patients with head and neck squamous cell carcinoma that has come
back (recurrent) or that has spread to other parts of the body (metastatic). Drugs used in
chemotherapy, such as docetaxel, cisplatin, carboplatin, and fluorouracil, work in different
ways to stop the growth of tumor cells, either by killing the cells, by stopping them from
dividing, or by stopping them from spreading. Monoclonal antibodies, such as bevacizumab, may
interfere with the ability of tumor cells to grow and spread. Bevacizumab may also make tumor
cells more sensitive to chemotherapy and stop the growth of head and neck cancer by blocking
blood flow to the tumor. It is not yet known whether combination chemotherapy is more
effective when given with or without bevacizumab in treating patients with head and neck
squamous cell carcinoma.
PRIMARY OBJECTIVES:
I. To compare the overall survival of patients with recurrent or metastatic head and neck
cancer treated with standard platinum-based chemotherapy with or without bevacizumab.
SECONDARY OBJECTIVES:
I. To assess toxicities with the addition of bevacizumab to each platinum-doublet
(cisplatin/docetaxel, carboplatin/docetaxel, cisplatin/fluorouracil [5-FU],
carboplatin/5-FU).
II. To compare the objective response rates and the progression-free survival achieved with
the above therapies.
III. To collect blood samples before and after therapy for future correlative studies.
IV. To collect tumor tissue samples available at baseline from prior diagnostic procedures
for future correlative studies.
OUTLINE: After the physician decides which chemotherapy doublet to use, patients are
randomized to 1 of 2 treatment arms for that chemotherapy combination.
ARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and
cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.
ARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and
cisplatin as in Arm IA.
ARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day
1. Courses repeat every 21 days in the absence of disease progression or unacceptable
toxicity.
ARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm
IIA.
ARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV
continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression
or unacceptable toxicity.
ARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm
IIIA.
ARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV
continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression
or unacceptable toxicity.
ARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm
IVA.
After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.
I. To compare the overall survival of patients with recurrent or metastatic head and neck
cancer treated with standard platinum-based chemotherapy with or without bevacizumab.
SECONDARY OBJECTIVES:
I. To assess toxicities with the addition of bevacizumab to each platinum-doublet
(cisplatin/docetaxel, carboplatin/docetaxel, cisplatin/fluorouracil [5-FU],
carboplatin/5-FU).
II. To compare the objective response rates and the progression-free survival achieved with
the above therapies.
III. To collect blood samples before and after therapy for future correlative studies.
IV. To collect tumor tissue samples available at baseline from prior diagnostic procedures
for future correlative studies.
OUTLINE: After the physician decides which chemotherapy doublet to use, patients are
randomized to 1 of 2 treatment arms for that chemotherapy combination.
ARM IA: Patients receive chemotherapy comprising docetaxel intravenously (IV) over 1 hour and
cisplatin IV over 1-2 hours on day 1. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.
ARM IB: Patients receive bevacizumab IV over 30-90 minutes on day 1 and docetaxel and
cisplatin as in Arm IA.
ARM IIA: Patients receive docetaxel IV over 1 hour and carboplatin IV over 30 minutes on day
1. Courses repeat every 21 days in the absence of disease progression or unacceptable
toxicity.
ARM IIB: Patients receive bevacizumab as in arm IB and docetaxel and carboplatin as in Arm
IIA.
ARM IIIA: Patients receive cisplatin IV over 1-2 hours on day 1 and fluorouracil IV
continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression
or unacceptable toxicity.
ARM IIIB: Patients receive bevacizumab as in Arm IB and cisplatin and fluorouracil as in Arm
IIIA.
ARM IVA: Patients receive carboplatin IV over 30 minutes on day 1 and fluorouracil IV
continuously on days 1-4. Courses repeat every 21 days in the absence of disease progression
or unacceptable toxicity.
ARM IVB: Patients receive bevacizumab as in Arm IB and carboplatin and fluorouracil as in Arm
IVA.
After completion of study treatment, patients are followed up every 3 months for 2 years and
then every 6 months for 3 years.
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed squamous cell cancer of
the head and neck (SCCHN), from any primary site, including unknown primary cancers of
the head and neck; patient must not have nasopharyngeal carcinoma of histologic types
World Health Organization (WHO) 2 or 3 or squamous cell carcinoma that originated in
the skin
- Patients must have SCCHN that is either (a) recurrent, judged incurable by surgery or
radiation or (b) metastatic; NOTE: Patients who refuse radical resection for recurrent
disease are eligible; NOTE: A second primary squamous cell carcinoma of the head and
neck is allowed if eligibility is based on a recurrent or metastatic first primary
squamous cell carcinoma of the head and neck
- No prior chemotherapy or biologic/molecular targeted therapy for recurrent or
metastatic SCCHN
- Patients may have received one regimen of induction, concomitant
chemoradiotherapy and/or adjuvant chemotherapy as part of initial potential
curative therapy but must not have received prior chemotherapy for recurrent or
metastatic disease
- A minimum of 4 months is required between last dose of chemotherapy or
chemoradiotherapy and study treatment; in addition patients must be
progression-free for at least 4 months after completion of chemotherapy or
chemoradiotherapy or radiation plus cetuximab given with a curative intent;
(cetuximab therapy: 4 months is required between last dose of chemotherapy or
chemoradiotherapy and study treatment if part of concurrent regimen, 8 weeks if
part of adjuvant regimen post radiation)
- Patients having progression after 2 cycles of induction chemotherapy are not
eligible for the study
- No prior bevacizumab is allowed
- A maximum of one prior radiotherapy regimen, curative or palliative, to the head and
neck is allowed; if the radiation is combined with chemotherapy and/or cetuximab, a
minimum of 4 months must elapse between the end of radiotherapy and registration; if
the radiation is given alone, a minimum of 8 weeks must elapse between the end of
radiotherapy and registration; a minimum of 3 weeks must elapse between prior
radiation to other areas and registration
- Patients must not be receiving any other investigational agent while on the study
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Patients must have recovered to grade 1 or better from any acute effects of prior
surgery, chemotherapy, or radiation therapy, and should be > 4 weeks post surgery;
chronic late xerostomia, speech and swallowing abnormalities resulting from prior
radiation or surgery are permitted if nutritional status is stable
- Patients must have measurable disease based on Response Evaluation Criteria in Solid
Tumors (RECIST); baseline measurements and evaluations of all sites of disease must be
obtained =< 4 weeks prior to randomization; disease in previously irradiated sites is
considered measurable if there has been unequivocal disease progression or
biopsy-proven residual carcinoma following radiation therapy; persistent disease after
radiotherapy must be biopsy proven at least 8 weeks after completion of radiation
therapy; (radiographic findings are acceptable providing that clear-cut measurements
can be made)
- Absolute neutrophil count (ANC) >= 1500/mm^3
- Hemoglobin (Hgb) >= 8.0 g/dL
- Platelet count >= 100,000/mm^3
- Creatinine clearance of >= 60 ml/min; creatinine clearance may be measured or
calculated; if calculating, creatinine clearance, use the Cockroft-Gault formula
- Total bilirubin within normal limits (must be obtained =< 2 weeks prior to
randomization)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the
range allowing for eligibility
- Alkaline phosphatase normal AND AST or ALT =< 5 x upper limit of normal (ULN)
- Alkaline phosphatase > 1 but =< 2.5 x ULN AND AST or ALT > 1 but =< 1.5 x ULN
- Alkaline phosphatase > 2.5 but =< 5 x ULN AND AST or ALT normal
- Alkaline phosphatase must be within the range allowing for eligibility
- Urine dipstick must be =< 0-1+ within 2 weeks (14 days) of randomization; if urine
dipstick result is > 1+, a calculation of urine protein creatinine (UPC) ratio is
required; patients must have a UPC ratio < 1.0 to participate in the study; NOTE: UPC
ratio of spot urine is an estimation of the 24 urine protein excretion - a UPC ratio
of 1 is roughly equivalent to a 24-hour urine protein of 1 gm
- No known brain metastases
- Patients who meet the following criteria will be excluded:
- Tumors that invade major vessels (e.g. the carotid) as shown unequivocally by
imaging studies
- Central (i.e. within 2 cm from the hilum) lung metastases that are cavitary as
shown unequivocally by imaging studies
- Any prior history of bleeding related to the current head and neck cancer
- History of gross hemoptysis (bright red blood of 1/2 teaspoon or more per episode
of coughing) =< 3 months prior to enrollment
- No history of coagulopathy or hemorrhagic disorders
- Patients should not have a history of thrombosis (e.g. pulmonary embolism or deep
venous thrombosis) currently requiring therapeutic anticoagulation (prophylactic use
of warfarin 1 mg per day is allowed) and international normalized ratio (INR) should
be < 1.5 at registration
- Patients must not be receiving chronic daily treatment with aspirin (> 325 mg/day) or
non-steroidal anti-inflammatory agents (NSAID's) known to inhibit platelet function;
the use of anti-platelet agents (e.g. dipyridamole [Persantine], ticlopidine [Ticlid],
clopidogrel [Plavix]) is allowed only if patient is not receiving aspirin or NSAID's
known to inhibit platelet function
- No hypercalcemia related to head and neck cancer
- Patients with a prior history of squamous cell or basal carcinoma of the skin or in
situ cervical cancer must have been curatively treated; patients with a history of
other prior malignancy must have been treated with curative intent and must have
remained disease-free for 3 years post diagnosis
- No current peripheral neuropathy >= grade 2 at time of randomization
- Patients must not have any co-existing condition that would preclude full compliance
with the study
- No prior history of severe hypersensitivity reaction to docetaxel or other drugs
formulated with polysorbate 80, if the physician's choice of chemotherapy regimen is
docetaxel
- All patients must have blood pressure =< 150/90 =< 2 weeks prior to randomization;
patients with history of hypertension must be well-controlled upon study entry (=<
150/90) on a stable regimen of anti-hypertensive therapy
- No major surgical procedure, open biopsy, or significant traumatic injury within 28
days prior to study enrollment, or anticipation of need for major surgical procedure
during the course of the study
- No unstable angina or myocardial infarction within the previous 6 months; no
symptomatic congestive heart failure, New York Heart Association (NYHA) grade II or
greater; no history of aortic dissection or presence of aneurysm > 6 cm (or at high
risk for rupture); no serious cardiac arrhythmia requiring medication (history of
chronic atrial fibrillation or other atrial arrhythmia with controlled rate on
medication is allowed); no clinically significant peripheral vascular disease
manifested by intermittent claudication or need for vascular intervention; no history
of aortic dissection; no history of any central nervous system (CNS) cerebrovascular
ischemia or stroke within the last 6 months; no active serious infection
- Patients should not have prior history of a serious human anti-human antibody (HAHA)
reaction; patients with known hypersensitivity to Chinese hamster ovary cell products
or other recombinant human antibodies are not eligible
- Women must not be pregnant or breast feeding; pregnant women are excluded from this
study; women of child-bearing potential and men must agree to total abstinence or to
use adequate hormonal or barrier method of birth control prior to study entry and for
the duration of study participation; should a woman become pregnant or suspect she is
pregnant while in this study, she should inform her treating physician immediately;
all females of childbearing potential must have a blood test or urine study within 2
weeks prior to randomization to rule out pregnancy
- Human immunodeficiency virus (HIV)-positive patients receiving combination
anti-retroviral therapy are excluded from the study; appropriate studies will be
undertaken in patients receiving combination anti-retroviral therapy when indicated
- No history of abdominal fistula, gastrointestinal perforation, or intra-abdominal
abscess within 6 months prior to registration
We found this trial at
795
sites
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Tufts Medical Center Tufts Medical Center is an internationally-respected academic medical center – a teaching...
Click here to add this to my saved trials
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
Holy Cross Hospital While spirituality plays an essential role in the way that we minister...
Click here to add this to my saved trials
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
1800 West Charleston Boulevard
Las Vegas, Nevada 89102
Las Vegas, Nevada 89102
(702) 383-2000
University Medical Center of Southern Nevada University Medical Center is dedicated to providing the highest...
Click here to add this to my saved trials
529 West Markham Street
Little Rock, Arkansas 72205
Little Rock, Arkansas 72205
(501) 686-7000
University of Arkansas for Medical Sciences The University of Arkansas for Medical Sciences (UAMS) in...
Click here to add this to my saved trials
401 College Street
Richmond, Virginia 23298
Richmond, Virginia 23298
(804) 828-0450
Virginia Commonwealth University Massey Cancer Center Founded in 1974, VCU Massey Cancer Center is a...
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
Click here to add this to my saved trials
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
170 North 1100 East
American Fork, Utah 84003
American Fork, Utah 84003
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Emory University Hospital Midtown Emory University Hospital Midtown is a 511-bed community-based, acute care teaching...
Click here to add this to my saved trials
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
Piedmont Hospital For more than a century, Piedmont Healthcare has been a recognized leader in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
401 North Broadway
Baltimore, Maryland 21287
Baltimore, Maryland 21287
410-955-5000
Johns Hopkins University-Sidney Kimmel Cancer Center The name Johns Hopkins has become synonymous with excellence...
Click here to add this to my saved trials
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
Summa Barberton Hospital Summa Barberton Hospital is a full member of Summa Health System and...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mary Rutan Hospital The hospital was endowed by the sale of a farm in Ridgeway...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Mid Dakota Clinic, PC We're your family clinic, with the doctors you know and trust...
Click here to add this to my saved trials
Saint Alexius Medical Center St. Alexius Medical Center is a 306-bed, full-service, acute care medical...
Click here to add this to my saved trials
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Click here to add this to my saved trials
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Fairview Ridges Hospital Fairview Ridges Hospital is a 150-bed, Level III Trauma Care facility, offering...
Click here to add this to my saved trials
400 South Clark Street
Butte, Montana 59701
Butte, Montana 59701
406-723-2500
Saint James Community Hospital and Cancer Treatment Center St. James Healthcare has played an important...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
Click here to add this to my saved trials